跳至主要内容
临床试验/JPRN-UMIN000016427
JPRN-UMIN000016427已完成未知

Multicenter study on the diagnosis of Alzheimer's disease with FDG-PET---SDAF-PET(study on diagnosis of Alzheimer's disease with FDG-PET) - SDAF-PET

ational Center for Geriatrics and Gerontology0 个研究点目标入组 138 人开始时间: 2015年2月3日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
138

研究概览

简要总结

The diagnostic performance of FDG-PET in the differential diagnosis of AD and FTLD is higher than that of p-tau181 in CSF. In addition, there is no problem with the safety of FDG-PET.

研究设计

研究类型
Observational

入排标准

年龄范围
55years-old 至 84years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • •1)Patients who have a previous history of or are under treatment for alcoholism. 2)Patients who have a previous history of or are under treatment for epilepsy. 3)Patients who have no more than 6 years of education. 4)Patients with diabetes who are currently receiving insulin therapy. 5)Patients who are currently receiving treatment with antidepressants, antipsychotics, or long-term sedative hypnotics (including anxiolytics). 6)Patients who had a diagnosis of major depression or bipolar disorder within the past year, those who have a previous history of schizophrenia, or those who are considered to have difficulty in completing the protocol due to severe manifestation of psychiatric symptoms, such as anxiety or irritation, within the last 3 weeks. 7)Patients with concurrent serious medical conditions (such as malignancy, heart failure, liver impairment, renal impairment, or endocrine disease). 8)Patients with MRI evidence of local lesions, such as cerebral infarcts, which might affect cognitive function.

研究者

发起方
ational Center for Geriatrics and Gerontology

相似试验